Lone H. Ottesen

2.3k total citations · 1 hit paper
56 papers, 1.4k citations indexed

About

Lone H. Ottesen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Lone H. Ottesen has authored 56 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 25 papers in Molecular Biology. Recurrent topics in Lone H. Ottesen's work include Lung Cancer Treatments and Mutations (14 papers), PI3K/AKT/mTOR signaling in cancer (8 papers) and Pancreatic and Hepatic Oncology Research (8 papers). Lone H. Ottesen is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), PI3K/AKT/mTOR signaling in cancer (8 papers) and Pancreatic and Hepatic Oncology Research (8 papers). Lone H. Ottesen collaborates with scholars based in United States, United Kingdom and South Korea. Lone H. Ottesen's co-authors include Anders Mellemgaard, Remy B. Verheijen, Lecia V. Sequist, Nasser K. Altorki, Helena A. Yu, Byoung Chul Cho, Ji‐Youn Han, Jong Seok Lee, Sergey Orlov and Paul Frewer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Hepatology.

In The Last Decade

Lone H. Ottesen

55 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

2020 295 citations Lecia V. Sequist, Ji‐Youn Han et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lone H. Ottesen United States	18	698	646	618	237	214	56	1.4k
Dana T. Aftab United States	20	574 0.8×	803 1.2×	882 1.4×	202 0.9×	417 1.9×	45	1.8k
Yiyi Yu China	21	460 0.7×	447 0.7×	741 1.2×	253 1.1×	327 1.5×	99	1.4k
Haitian Quan China	17	383 0.5×	492 0.8×	662 1.1×	111 0.5×	137 0.6×	30	1.3k
Dongmei Ji China	15	463 0.7×	392 0.6×	539 0.9×	120 0.5×	130 0.6×	92	1.2k
Harold Keer United States	21	1.2k 1.7×	1.3k 2.0×	627 1.0×	219 0.9×	610 2.9×	75	2.6k
Jessica Orf United States	7	437 0.6×	545 0.8×	507 0.8×	243 1.0×	204 1.0×	9	1.3k
Yu-Chien Chou United States	5	418 0.6×	445 0.7×	481 0.8×	241 1.0×	201 0.9×	5	1.1k
Frauke Bentzien United States	10	522 0.7×	821 1.3×	665 1.1×	372 1.6×	298 1.4×	12	2.1k
Soji Kakiuchi Japan	21	910 1.3×	998 1.5×	850 1.4×	132 0.6×	313 1.5×	41	1.9k
Zhong‐Zhe Lin Taiwan	22	552 0.8×	418 0.6×	740 1.2×	498 2.1×	332 1.6×	65	1.5k

Countries citing papers authored by Lone H. Ottesen

Since Specialization

Citations

This map shows the geographic impact of Lone H. Ottesen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lone H. Ottesen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lone H. Ottesen more than expected).

Fields of papers citing papers by Lone H. Ottesen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lone H. Ottesen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lone H. Ottesen. The network helps show where Lone H. Ottesen may publish in the future.

Co-authorship network of co-authors of Lone H. Ottesen

This figure shows the co-authorship network connecting the top 25 collaborators of Lone H. Ottesen. A scholar is included among the top collaborators of Lone H. Ottesen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lone H. Ottesen. Lone H. Ottesen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hamilton, Erika, Gerald S. Falchook, Judy S. Wang, et al.. (2024). Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial. Targeted Oncology. 19(6). 879–892. 3 indexed citations

Agapow, Paul‐Michael, et al.. (2023). Systematic review of time to subsequent therapy as a candidate surrogate endpoint in advanced solid tumors. Future Oncology. 19(23). 1627–1639. 2 indexed citations

Hansen, Thomas B., S. Cedrés, Charles Ricordel, et al.. (2023). Granular analysis of individual immune-related gene expression in a randomized phase I/II study of the oncolytic adenovirus, ONCOS-102, in combination with pemetrexed/cisplatin (P/C) in patients (pts) with unresectable malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology. 41(16_suppl). e20536–e20536. 1 indexed citations

Albigès, Laurence, Daniel Y.C. Heng, Jae‐Lyun Lee, et al.. (2022). Impact of MET status on treatment outcomes in papillary renal cell carcinoma: A pooled analysis of historical data. European Journal of Cancer. 170. 158–168. 7 indexed citations

Ottesen, Lone H., et al.. (2020). A Comprehensive Methodology to Systematically Identify Drug Hypersensitivity and Anaphylactic Reactions in Clinical Trial Databases. Pharmaceutical Medicine. 34(5). 335–345. 1 indexed citations

Någård, Mats, Mei-Lin Ah-See, Karen So, et al.. (2020). Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 86(1). 97–108. 8 indexed citations

Sequist, Lecia V., Jong Seok Lee, Ji‐Youn Han, et al.. (2019). Abstract CT033: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) withEGFR-mutant,MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Clinical Trials. CT033–CT033. 1 indexed citations

Choueiri, Toni K., Regina I. Jakacki, Dana Ghiorghiu, et al.. (2017). Savolitinib versus sunitinib in patients with MET-driven, unresectable and locally advanced or metastatic papillary renal cell carcinoma: SAVOIR, a randomised, phase III trial. Annals of Oncology. 28. v328–v328. 6 indexed citations

Yau, Thomas, Riccardo Lencioni, Wattana Sukeepaisarnjaroen, et al.. (2016). A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research. 23(10). 2405–2413. 58 indexed citations

10.

Kerklaan, Bojana Milojkovic, S. Slater, Michael Flynn, et al.. (2016). A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors. Investigational New Drugs. 34(3). 329–337. 21 indexed citations

11.

Kendra, Kari, Ruth Plummer, Ravi Salgia, et al.. (2014). A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics. 14(2). 461–469. 28 indexed citations

12.

Scagliotti, Giorgio V., Enriqueta Felip, Benjamin Besse, et al.. (2013). An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 8(12). 1529–1537. 34 indexed citations

13.

Dy, Grace K., Jeffrey R. Infante, Sabine Eckhardt, et al.. (2012). Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib. Investigational New Drugs. 31(4). 891–899. 4 indexed citations

14.

Srinivasan, Ramaprasad, Donald P. Bottaro, Toni K. Choueiri, et al.. (2012). Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644).. Journal of Clinical Oncology. 30(5_suppl). 372–372. 6 indexed citations

15.

Altorki, Nasser K., Michael J. Guarino, Harvey I. Pass, et al.. (2008). Preoperative treatment with pazopanib (GW786034), a multikinase angiogenesis inhibitor in early-stage non-small cell lung cancer (NSCLC): A proof-of-concept phase II study. Journal of Clinical Oncology. 26(15_suppl). 7557–7557. 28 indexed citations

16.

Pedersen, Mikkel W., Nina Marie Pedersen, Lone H. Ottesen, & Hans Skovgaard Poulsen. (2005). Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. British Journal of Cancer. 93(8). 915–923. 69 indexed citations

17.

Ottesen, Lone H., Jan Frystyk, Marianne Kiszka‐Kanowitz, et al.. (2002). Effects of octreotide on serum insulin-like growth factor I and insulin-like growth factor binding proteins in patients with cirrhosis. Scandinavian Journal of Clinical and Laboratory Investigation. 62(1). 39–47. 3 indexed citations

18.

Ottesen, Lone H., Niels Kristian Aagaard, Marianne Kiszka‐Kanowitz, et al.. (2001). Effects of a long-acting formulation of octreotide on renal function and renal sodium handling in cirrhotic patients with portal hypertension: A randomized, double-blind, controlled trial. Hepatology. 34(3). 471–477. 24 indexed citations

19.

Ottesen, Lone H., Else‐Marie Bladbjerg, Maher Osman, et al.. (1999). Protein C Activation during the Initial Phase of Experimental Acute Pancreatitis in the Rabbit. Digestive Surgery. 16(6). 486–495. 28 indexed citations

20.

Ottesen, Lone H., Allan Flyvbjerg, Preben Jakobsen, & Flemming Bendtsen. (1997). The pharmacokinetics of octreotide in cirrhosis and in healthy man. Journal of Hepatology. 26(5). 1018–1025. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact